MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD BDRX 深 滬
等待開盤 08-18 09:30:00 美东时间
7.04
0.000
0.00%
華盛通- 最 高7.2254
- 今 開7.2254
- 成交量 8752股
- 最 低 6.8228
- 昨 收 7.04
- 總市值 355.59万
- 52周最高 160.00
- 市盈率 靜 --
- 換手率 1.73%
- 52周最低 6.6228
- 委 比 -33.33%
- 總股本 50.51万
- 歷史最高 159417654.2112
- 量 比 0.43
- 振 幅 5.72%
- 歷史最低 6.8228
- 每 手 1
- 風險率 35.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Biodexa Pharmaceuticals Implements ADR Ratio Change
Biodexa Pharmaceuticals ( ($BDRX) ) just unveiled an update. On July 31, 2025, ...
07-31 21:59
Biodexa Pharma Advances Development eRapa, Oral Tablet Formulation Of Rapamycin, To Treat FAP Non-Surgically
Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company, reports making significant progress in developing eRapa, an oral tablet formulation of rapamycin, to treat FAP non-surgically. eRapa
07-28 19:10
ADR Ratio Change
On July 15, 2025, Biodexa Pharmaceuticals PLC announced a ratio change for its American Depositary Receipts (ADR), adjusting from 1 ADR representing 10,000 ordinary shares to 1 ADR representing 100,000 ordinary shares, effective July 31, 2025. ADR holders must exchange 10 old ADRs for 1 new ADR. This change aims to align the ADR price with Nasdaq's $1.00 minimum bid price requirement, though success is not guaranteed. Forward-looking statements a...
07-15 20:30
Biodexa Pharma Files CTA With EMA For Serenta Trial In Patients With Familial Adenomatous Polyposis
Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial inFamilial Adenomatous Polyposis (FAP)Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (NASDAQ:BDRX), a clinical stage biopharmaceutical
07-14 20:35
Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
Biodexa Pharmaceuticals has activated the first clinical study site for its Phase 3 Serenta trial, focusing on Familial Adenomatous Polyposis (FAP). The trial evaluates the safety and efficacy of eRapa, an mTOR inhibitor, offering a potential new treatment for FAP, a rare genetic condition with high risks of colorectal cancer. Biodexa received $20 million in grant funding from CPRIT to support this program. The trial is now enrolling participants...
06-25 12:30
Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)
Biodexa Pharmaceuticals has named its upcoming Phase 3 study for Familial Adenomatous Polyposis (FAP) "Serenta" and launched a dedicated website, www.serentatrial.com, to provide information for patients and healthcare professionals. Serenta highlights Biodexa's commitment to supporting the FAP community. The study focuses on eRapa, an oral mTOR inhibitor designed to address the poor bioavailability and toxicity of existing rapamycin forms. Addit...
06-23 12:30
Market-Moving News for June 18th
SRRK: 23% | Scholar Rock shares are trading higher after a study showed its new drug combination preserves muscle during tirzepatide-induced weight loss. RELI: 70% | Reliance Global shares are trading
06-18 19:29
Biodexa shares are trading higher after the company enrolled the first patient in its Phase 2a study of Tolimidone.
Biodexa shares are trading higher after the company enrolled the first patient ...
06-18 19:10
Result of General Meeting
Biodexa Pharmaceuticals PLC held a General Meeting on June 11, 2025, where four resolutions were passed. Resolutions 1 and 4 reduced the nominal value per ordinary share without changing the total number of shares. Resolutions 2 and 3 granted Directors authority to allot ordinary shares non-pre-emptively. Biodexa, a biopharmaceutical company, is developing eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone...
06-11 20:30
Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced the recruitment of the first patient in a Phase 2 study of tolimidone for Type 1 Diabetes (T1D). The study, initiated by the University of Alberta Diabetes Institute, will assess C-peptide and HbA1c levels, as well as hyperglycemic events in 12 patients across three dose groups. Tolimidone, a selective Lyn kinase activator, was initially developed by Pfizer but discontinued due to lack of effic...
06-04 12:30
